Clinical translation requires human CSF pharmacokinetic assays to prove BBB bypass, a rigorous dose-escalation Phase I trial to establish a safe human NOAEL for chronic dosing, and an RCT utilizing precise neurocognitive testing (e.g., MoCA) to confirm that murine transcriptomic shifts yield functional neuroprotection in humans
Have plenty or real food and colourful food
While microdosing programs are not intended for significant weight loss, program participants may experience reduced appetite and cravings, leading to gradual, sustained weight management
Shipping delays, payment processing holds, or supplier stock issues can create 35 day gaps, and even a single missed injection disrupts steady-state antioxidant activity
Most patients report early changes (improved skin feel, reduced inflammation, or fewer shedding hairs) by the end of week 3 or 4
Steroid injections to treat inflammation